Some mutations of exon-7 in cytochrome P450 gene 3A4 and their effect on 6β-hydroxylation of cortisol

Bulletin of Experimental Biology and Medicine

Volumn 141, Issue 6, 2006, Pages 701-703

  Shchepotina, E G ^a   Vavilin, V A ^a   Goreva, O B ^a   Lyakhovich, V V ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND BIOPHYSICS   (Russian Federation)

Author keywords

CYP3A4; CYP3A4 activity; Genetic polymorphism

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A; CYTOCHROME P450 3A17; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HYDROCORTISONE; NIFEDIPINE; UNCLASSIFIED DRUG;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HYDROXYLATION; INCIDENCE; METABOLIC RATE;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FINLAND; GENE FREQUENCY; HUMANS; HYDROCORTISONE; HYDROXYLATION; MUTATION; SIBERIA;

EID: 33748576575     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-006-0257-2     Document Type: Article

References (15)

1. V. A. Vavilin, E. G. Shchepotina, N. A. Manankin, et al., Byull. Eksp. Biol. Med., 138, No. 9, 272-274 (2004).
2. G. V. Ramenskaya, E. A. Smolyarchuk, and V. G. Kukes, Ibid., Suppl. 1, 71-73 (2002).
3. D. Dai, J. Tang, R. Rose, et al., J. Pharmacol. Exp. Ther., 299, No. 3, 825-831 (2001).
4. E. Garcia-Martin, C. Martinez, R. M. Pizarro, et al., Clin. Pharmacol. Ther., 71, No. 3, 196-204 (2002).
5. K. P. Hsieh, Y. Y. Lin, C. L. Chang, et al., Drug. Metab. Dis., 29, No. 3, 268-273 (2001).
6. I. Koch, R. Weil, R. Wolbold, et al., Ibid., 30, No. 10, 1108-1114 (2002).
7. P. Kuehl, J. Zhang, Y. Lin, et al., Nat. Genet., 27, No. 4, 383-391 (2001).
8. L. M. Kunkel, K. D. Smith, S. N. Boyer, et al., Proc. Natl. Acad. Sci. USA., 74, No. 3, 1245-1249 (1977).
9. S. J. Lee, D. A. Bell, S. J. Coulter, et al., J. Pharmacol. Exp. Ther., 313, No. 1, 302-309 (2005).
10. V. Ozdemir, W. Kalowa, B. K. Tang, et al., Pharmacogenetics, 10, No. 5, 373-388 (2000).
11. F. Sata, A. Sapone, G. Elizondo, et al., Clin. Pharmacol. Ther., 67, No. 1, 48-56 (2000).
12. T. Shimada, H. Yamazaki, M. Mimura, et al., J. Pharmacol. Exp. Ther., 270, No. 1, 414-423 (1994).
13. J. C. Stevens, R. N. Hines, C. Gu, et al., Ibid., 307, No. 2, 573-582 (2003).
14. K. E. Thummel and G. R. Wilkinson, Annu. Rev. Pharmacol. Toxicol., 38, No. 1, 389-430 (1998).
15. A. Westlind, S. Malmebo, I. Johansson, et al., Biochem. Biophys. Res. Commun., 281, No. 5, 1349-1355 (2001).